Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X Conference

DEVON, Pa., July 07, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE ), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced two poster presentations at the 18th NFXF International Fragile X Conference, being held July 14-17, 2022, in San Diego, Calif. In addition, Zynerba management will present a company presentation during the conference's Keynote – Industry Updates session. Copies of the presentation and posters will be made available on the Zynerba corporate website following the presentations at www.zynerba.com/publications . Corporate Presentation Details Title: Zynerba Pharmaceuticals - Development of ZYN002 (Zygel™) for the Treatment of Behavioral Symptoms in Fragile X Syndrome: Partnering to advance the care of children and adolescents with Fragile X Syndrome Date: Friday, July 15, 2022 Time: 3:15 p.m. – 4:30 p.m. PT (6:15 – 7:30 p.m. ET) Location: Town and Country – A, Town and Country Resort, San Diego, Calif. Poster Presentation Details Title: Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents With Fragile X Syndrome (ZYN2-CL-017) Title: RECONNECT (ZYN2-CL-033): Design of a Phase 3 Trial of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents With Fragile X Syndrome Based Upon Learnings From CONNECT-FX (ZYN2-CL-016) Date: Friday, July 15, 2022 Full story available on Benzinga.com